Patient perspectives on barriers to rTMS for peripartum depression Authors: Huda F Al-Shamali, Rachael Dong, Margot Jackson, Lisa Burback, Gina Wong, Bo Cao, Xin-Min Li, Andrew J Greenshaw, Yanbo Zhang Published: 2026 ABSTRACT AbstractBackgroundPeripartum depression (PPD) is often underdiagnosed and left untreated. PPD can negatively impact maternal health and child development and is associated with an increased risk of maternal suicide. Effective and safe treatments that are viewed as acceptable by patients are needed. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulatory treatment that has the potential to meet this need.MethodsThe objective was to identify the level of awareness of rTMS among participants who experienced depressive symptoms during the peripartum period and to understand the barriers and facilitators that impact access to rTMS. Three focus groups with a total of 9 participants who experienced depressive symptoms during the peripartum period were conducted. A descriptive interpretive thematic analysis was completed.ResultsThe majority of participants (6 out of 9; 67%) never heard of rTMS prior to this study. Following a brief description of rTMS by the researcher, all participants expressed an interest in rTMS and a willingness to learn more about it as a treatment for PPD; however, some expressed reservations about receiving the treatment during pregnancy due to uncertainty regarding whether it could have an impact on their child’s well-being. The following four themes were identified as the primary factors that impact access to rTMS: limited awareness of rTMS’s existence, financial challenges, physical accessibility, and weighing the pros and cons of medication vs. rTMS.ConclusionsIncreasing the general public’s and their health providers’ awareness regarding rTMS and other novel treatments is a crucial step toward improving access to care. Greater awareness of rTMS for PPD may support earlier recognition of appropriate candidates, improve referral pathways, and reduce barriers related to knowledge, accessibility, and treatment hesitancy. Further research is needed to continue evaluating the safety, effectiveness, and accessibility of rTMS for PPD.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12888-026-08234-3.Keywords: Peripartum depression, Postpartum depression, Repetitive transcranial magnetic stimulation, Education, Access, Neuromodulation Introduction Peripartum depression (PPD) is a major depressive episode with onset during pregnancy or within four weeks postpartum that is characterized by persistent sadness, lack of interest, fatigue, difficulties in concentration, sleep and appetite disturbances, and suicidal ideation and attempts [1]. Although onset occurs during pregnancy or within the first four weeks postpartum, symptoms may persist throughout the first postpartum year if left untreated. PPD impacts nearly one in five women, making it one of the most common medical complications associated with this period [2, 3]. Despite its prevalence and critical impact on maternal health and infant development and attachment [4–10], PPD is often underdiagnosed and left untreated [11]. This is concerning given the connection between PPD and a heightened risk of maternal suicide, especially within the first year postpartum, indicating a need for enhanced screening and treatment initiatives to address this issue [12]. Treatment approaches for PPD vary according to severity. Psychotherapy is considered first-line treatment for mild to moderate cases; however, it may be insufficient for individuals with more severe or persistent symptoms [13, 14]. For moderate to severe depression, including treatment-resistant depression (TRD), pharmacotherapy and electroconvulsive therapy are evidence-based and effective interventions [13, 14]. In cases of TRD, pharmacological management may involve dose escalation, switching agents, or augmentation strategies, which can further complicate decision-making during pregnancy and lactation. During pregnancy treatment decisions often involve careful consideration of potential risks (i.e., fetal exposure and neonatal adaptation symptoms) [14–16] and personal hesitancy [17, 18]. In the postpartum period, considerations include medication transfer through breastmilk and the impact of side effects on maternal functioning [19, 20]. These factors, combined with personal values and perceptions of risk, can influence treatment preferences. In this context, there has been growing interest over the past two decades in safe, effective, and patient-accepted treatment alternatives for severe PPD. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that has demonstrated efficacy in TRD [21], as well as in anxiety disorders [22], obsessive-compulsive disorder [23], and other psychiatric conditions. The antidepressant effects of rTMS are achieved by inducing electrical currents into a coil that generates a magnetic field that depolarizes neurons in the cortex, usually the dorsolateral prefrontal cortex [24]. In 2002 and 2008, rTMS received approval from Health Canada and the Food and Drug Administration (FDA), respectively, as a treatment for TRD, defined by the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study as failure to achieve remission after at least two adequate antidepressant trials (adequate dose and duration ≥ 6 weeks each) [25, 26]. rTMS is recognized for its safety, exhibiting minimal and generally transient side effects. The most frequently reported side effects include mild and temporary headaches (25–30%) and scalp discomfort at the stimulation site (35–40%) [27]. Additionally, the likelihood of rTMS triggering hypomania stands at 0.9%, a rate comparable to that associated with antidepressant medications [28]. The risk of seizure is rare (approximately 0.03%) and is predominantly observed in patients with a pre-existing seizure disorder [29]. In contrast, the seizure risk linked to antidepressant use ranges from 0.1 to 0.6% and spontaneously occurs in 0.07–0.09% of the general population [20]. Importantly, rTMS is a non-systemic intervention, thereby not resulting in fetal drug exposure during pregnancy and transfer through breastmilk in the postpartum period. Although research on rTMS for PPD remains limited, available evidence suggests it is well tolerated and may represent a safe and effective treatment option in this population; however, larger randomized controlled trials are needed to further establish its efficacy and safety [30–36]. In Canada, rTMS is available as a treatment for depression and other various psychiatric conditions within both public health services and private clinics. Unfortunately, its uptake among individuals with PPD remains remarkably low. To our knowledge, this is the first study that utilizes focus groups to explore perceptions of barriers and facilitators influencing access to rTMS among individuals with PPD, particularly in cases where it may be clinically indicated. By examining the barriers and facilitators to accessing rTMS treatment, we aim to inform future initiatives that can contribute to the development of more comprehensive and effective treatment strategies for PPD to improve mental health outcomes for mothers and their children. Methods This qualitative study utilized a descriptive interpretive approach to explore the factors impacting access to rTMS treatment among adult pregnant and postpartum individuals by gathering contextual data on participants’ experiences, barriers, facilitators, and recommendations. Participant recruitment Participants were recruited through purposive sampling, targeting individuals who experienced depressive symptoms during the peripartum period. Recruitment was conducted through local health clinics, community organizations (i.e., Canadian Mental Health Association), online platforms (i.e., Instagram), and a partnership with a national organization (Mood Disorders Society of Canada). Data collection Three semi-structured focus groups were conducted over ZOOM, each involving a different group of participants and lasting approximately 30 to 60 min. Before the focus groups, participants completed a demographic questionnaire that included their gender, age, ethnicity, and the first three digits of their postal code. The focus group discussion consisted of six open-ended questions and was facilitated by a researcher trained in qualitative methodology (Supplementary Materials 1). Focus groups were video and audio-recorded with participants’ consent, and comments added through the chat function were also collected. The recordings were automatically transcribed by ZOOM, then anonymized and verified by a researcher to ensure accurate verbatim transcription. Data analysis Thematic analysis was used to analyze the focus group data following Braun and Clarke’s six-phase framework [31]. Initially, the researchers familiarized themselves with the content through transcript verification or by reading and summarizing key points of the transcript. Subsequently, an inductive approach was employed to generate initial codes using the NVivo software, capturing key ideas and patterns evident within the data. Through team discussion, codes were organized into themes. The identified themes were then refined, defined, and named to accurately reflect their underlying content and meaning. Finally, the findings were synthesized and supplemented by excerpts from the transcripts to illustrate each theme. Ethics Ethical approval was obtained from the University of Alberta Research Ethics Office (Pro00114151) and this study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants. Before the focus group, participants received a comprehensive information form detailing the study’s purpose, procedures, and their rights as participants. At the start of each focus group, the main points from the form were presented again ensuring participants’ understanding and reinforcing their consent to participate. It was made clear that their active involvement in the discussions implied consent. Results Participant characteristics Twenty participants signed-up for the focus groups and nine attended, representing a participation rate of 45%. The participants had a mean age of 33.8 years [SD = 5.1], ranging from 26 to 39 years. All participants identified as women, with the majority being Caucasian (7 out of 9; 77.8%), one identifying as First Nations/Inuit/Metis (1 out of 9; 11.1%), and one as Latina/Hispanic (1 out of 9; 11.1%). Eight participants resided in urban communities, while one did not provide their postal code. Regarding familiarity with rTMS, six participants never heard of it, one received rTMS twice (for major depressive disorder and for PPD with comorbid anxiety), one was scheduled to receive rTMS for PPD, but opted to continue with medication first, and the remaining participant heard of rTMS but lacked detailed knowledge about it. After receiving a concise overview of rTMS, all participants expressed interest in considering it as a potential treatment for PPD and indicated their willingness to attend an information session if available. They emphasized the importance of gaining further understanding of its mechanism, potential side effects, and hearing testimonials from others who have undergone the treatment. I don’t know how comfortable I would be just saying yes, given what I know right now, which is very minimal. But to be honest, umm, I’m willing to try anything just because my depression is so bad, and medication seems like I’m just taking candy every day as opposed to something that’s useful. So, if it’s something that could potentially work, then absolutely, I would try it. Three of the participants who expressed interest in undergoing rTMS specified that they would be open to receiving it postpartum. However, they expressed reservations about undergoing the treatment during pregnancy due to concerns about its potential impact on their child’s well-being. I don’t know if I would choose to receive this treatment while pregnant, although I didn’t have depression while pregnant, so I, I guess I can’t really say, like, how desperate I was for a solution. But I think I would want to read a lot of research on pregnant women, and the outcomes for the baby before committing. Barriers and facilitators to rTMS treatment Four themes were identified regarding factors influencing an individual’s ability to receive rTMS while pregnant or postpartum. The themes are (1) limited awareness of rTMS’s existence, (2) financial challenges, (3) physical accessibility, and (4) weighing the pros and cons of medication vs. rTMS. Limited awareness of rTMS’s existence All participants indicated that the widespread lack of awareness regarding the existence of rTMS, by both patients and health providers, is the primary perceived barrier to access. There was a specific emphasis on the critical role of improving the knowledge of healthcare providers, particularly those who interact directly with the birthing population, such as obstetricians/gynecologists (OB/GYN), family doctors, and doulas. These professionals were highlighted as the primary, and often sole, source of information and the major facilitator for accessing treatment. It’s one thing for patients to know, but I think it’s another thing for, umm, medical people to know what’s going on…with mental health being so prevalent in so many people, umm, I find that a lot of physicians aren’t really up to date on what they can, like what options they can provide for their patients…it’s important that, you know, OB/GYNs and your family doctors know what treatments are available and safe while you’re pregnant. Umm, otherwise they’re just, you know, they might not have the right information to help. Ways of improving knowledge were also extensively discussed. In terms of patient awareness, providing information through home visits by nurses, posters at doctors’ offices, social media, news articles, commercials, and radio ads were all mentioned. Additionally, speaking about rTMS during community groups for postpartum depression was mentioned as being possibly beneficial. I was part of a, a community group for postpartum depression…we were presented sessions on a whole bunch of different things…if the rTMS could be a part of something that a community group would talk about, then that would reach the population that needs it. Word of mouth and real-life testimonies were also cited as important factors for improving awareness of rTMS. I was already aware of the treatment, even a decade ago, because I had a friend in a similar situation, and she’d done this treatment…and she had good results, so I not only trusted the treatment, I accepted the option that the doctors gave me. Regarding health providers, providing seminars and conferences focused on rTMS and maternal mental health was the most repeated recommendation. Just from speaking with my own family doctor…like you have to do so many seminars and conferences and, and whatnot per year…have it brought to those conferences, and don’t make it just, like, OB-G specific or psych-psychiatry, psychology-specific, make it so that, like, [general practitioners, nurse practitioners, and medical doctors],…make it so that it’s known throughout the whole medical profession, not just specific, umm, areas of the medical world. Financial challenges The cost was another major concern, with the question of “Is this covered under health benefits” repeated multiple times across the focus groups. The two participants with experience accessing rTMS noted that they did not know it could be received through the public health system, and they went through the private clinic route. The participant who postponed their rTMS appointment stated that they were quoted $3000 for 15 sessions, and this was a major reason they are delaying treatment. The participant who did receive rTMS said: But I didn’t even know, it, it could be covered by [XX]…and not even my insurance cover…So, I have to hire like a separate Blue Cross plan with a specific configuration that had most, they offer most coverage…[rTMS is] very expensive for most people, so that will be a barrier for me in the future. Needing to find childcare during appointments, especially postpartum, was another point of concern. Being able to bring their child with them was mentioned as a possible solution, but with the caveat that their child may act as a distraction to them. Additionally, needing to take time off work to attend appointments if they were not yet on maternity leave was mentioned by a participant who said: If I had opted to do this treatment when I was pregnant, I was already taking a lot of time off work, like to go to a doctor’s appointment or go to, umm, get an ultrasound…so I think that would be a barrier if you weren’t already on mat leave…I know for me, I wouldn’t have been able to do it while I was in work. Physical accessibility The location of the treatment center is an important factor considered by the participants, especially considering the frequency of the rTMS treatment sessions (5 days a week for 4–6 weeks). For me, it would also depend on…where you can access the treatment. ‘Cause if I have to drive two hours to access treatment, then I probably wouldn’t do it. Another participant commented the following regarding the time commitment: If I were postpartum, and I needed to go five days a week for four to six weeks with a baby-No. [laughs] Can you come to me? An accessibility concern presented by the participant who received rTMS during pregnancy was the comfort level of the actual rTMS treatment session. She noted that the chair she had sat on was very uncomfortable and prevented her from receiving all prescribed treatment sessions, especially near the end of her pregnancy. I was pregnant, it was in my last couple months, and so, it was very uncomfortable…by the time of my appointment, I got nervous about it, and I left really angry because I was so uncomf-uncomfortable in the seat, and I told the doctors like almost every day…I had to ask to finish the treatment before because I couldn’t go anymore… I was feeling bad on that table. She was given a portable, battery-run, experimental device to continue the treatment at home following her delivery. However, she also discontinued that treatment early as she had trouble receiving it while also taking care of two children. She also noted that the portable device was less effective than rTMS and she would not be willing to try it again. Conversely, she is willing to try rTMS again if she needs it. Weighing the pros and cons of medication vs. rTMS An attractive quality of rTMS was its non-invasive nature and limited side effects. Some participants mentioned preferring rTMS over medication as they feared the potential impact medication could have on their baby. This fear was also shared by some of their health providers and was noted as a reason for delayed or stopped treatment: When I found out I was pregnant, my doctor was fairly…like an old school kind of doctor, and uh, he was like, “nope, you can’t take anything.” And I was like, “buhhh, that’s not a good idea.” So, I ended up having to, like, I stopped because he was my doctor, and then, uhh, it didn’t go well. One participant mentioned that her first experience with rTMS was outside of pregnancy, and she received concurrent medication and rTMS treatments. She remarked that this combined approach was highly effective, likening the experience to feeling ‘like a magical unicorn’ after the treatment. In her second experience, while pregnant, she only received rTMS and noticed that it was not as effective as her first experience. However, in the second time, it’s hard to tell, because I was not on the medication, and I was pregnant. So there is lots of things going on in our body. Uhh, [sighs], I think it helped, but not as much as the first time, absolutely not, uhh, compared to my first time. And the sensation that, that I have, is that TMS, it, umm, intensified the medication. Discussion This research identified a significant interest among participants in learning more about rTMS as a potential treatment for PPD. The focus groups revealed that the adoption of rTMS is hindered by several key factors: a general lack of awareness about rTMS among both patients and healthcare providers, accessibility issues, and financial concerns, including the cost of treatment, childcare expenses, and the potential cost of taking time off work. Additionally, the focus groups engaged in a brief discussion on the advantages and drawbacks of using medication during the peripartum period and in combination with rTMS. The focus groups highlighted patients’ and health providers’ limited awareness of rTMS as a potential treatment for PPD, emphasizing the need for targeted efforts to improve knowledge and address financial and access related barriers. The interest by participants to learn more about rTMS as a treatment for PPD is a significant finding and highlights the marked need for safe and effective treatments for this population. Increasing patients’ and healthcare providers’ knowledge of the evidence base for rTMS for PPD may begin to address this need. These findings align with qualitative interview evidence showing that limited awareness of rTMS among patients and healthcare providers is a key barrier to its use in PPD, with interest emerging once the treatment is explained. Participants also identified access barriers such as cost, availability, and referral challenges, underscoring the need for targeted education and system-level efforts to improve access to rTMS for this population [32]. The critical role health providers play in shaping patients’ knowledge, treatment preferences, and access is particularly salient, as provider recommendations strongly influence care pathways [33]. The limited knowledge of healthcare providers about rTMS is a critical barrier to treatment accessibility and can be addressed through conferences, workshops, and educational material focused on rTMS and other novel treatments [34, 35]. Importantly, knowledge mobilization should extend beyond mental health specialists to all health providers who routinely interact with patients during the peripartum period and facilitate treatment or referrals, such as general practitioners, nurse practitioners, and obstetric care providers. Community-based supports, such as doulas, may also play an important role in increasing awareness of available treatment options and supporting pathways to care. At a systems level, clinical practice guidelines further shape clinician behaviour and treatment availability. In Canada, the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines recommend rTMS as a first-line neurostimulation treatment for individuals who have not benefited from at least one adequate antidepressant trial [20] or for patients for whom antidepressants are unsuitable (e.g., due to side effects or contraindications) [36]. However, this requirement may pose a limitation for peripartum populations, in whom antidepressant treatments are often avoided, delayed, or declined due to safety concerns during pregnancy and breastfeeding. As a result, individuals with PPD may be less likely to meet guideline-based eligibility criteria for rTMS, even when it represents a clinically appropriate option, particularly in the context of limited provider awareness. Within this context, family practitioners are positioned to facilitate earlier identification of appropriate candidates and initiate timely referrals to a psychiatrist. In Canada, however, the average wait time from general practitioner referral to specialist-prescribed elective mental health treatment is 29.2 weeks [37], contributing to substantial delays in care. Increasing primary care providers’ awareness of rTMS may support earlier recognition of treatment-resistant or medication-averse cases and reduce delays in referral to a psychiatrist. Importantly, expanding the role of primary care does not imply bypassing specialist involvement. In many publicly funded and hospital-based services, rTMS requires psychiatric assessment or ongoing oversight. Strengthening collaborative referral pathways between primary care and specialist perinatal mental health services is therefore essential to ensure safe, guideline-concordant delivery of care. Such coordination may be particularly important for women of lower socioeconomic status and women of colour, who experience higher rates of depression during pregnancy and are more likely to access care through general practitioners rather than psychiatrists [38, 39]. Improving primary care awareness and referral processes may help mitigate disparities in access, particularly within a publicly funded rTMS service model. Although rTMS is also available through private clinics in Canada, access in these settings often depends on out-of-pocket payment or private insurance coverage, which may further exacerbate inequities for peripartum populations. These financial barriers may also reflect the inconsistent availability of publicly funded rTMS services across Canada, as only some provinces currently provide public coverage for TRD. Additionally, because participants’ diagnostic status and treatment eligibility were not systematically assessed, it remains unclear whether reported out-of-pocket costs reflected true ineligibility for publicly funded services or limited awareness of available coverage and referral pathways. These findings highlight both structural inequities in funding and the need for improved patient and provider awareness regarding access options. Knowledge translation to the general public is also an important step towards increasing access to novel treatments for PPD. Increasing public awareness gives agency to patients which may lead to increased confidence and acceptance of their condition and proposed treatment; an important aspect mentioned by the participant who received rTMS after her friends positive experience. As such, rTMS recipient case studies and testimonies could be shared through social media as well as traditional news media as these are impactful methods of informing the general public about new treatments and have the potential to change behaviour [40, 41]. At present, there are several logistical considerations and barriers impacting rTMS access. Although most participants lived in urban communities, concerns regarding travel distance appeared to reflect perceived accessibility barriers and uncertainty about whether rTMS services would be available outside larger metropolitan centres. In its current form, rTMS is time-intensive and has limited portability, requiring patients to be in the clinic for treatment. New parents, those in rural communities without access to an rTMS device, and others with limited time and mobility may be particularly impacted. Intermittent theta-burst stimulation (iTBS) is a quicker form of rTMS that has shown promise as an effective treatment for depression with a 3-minute treatment session [42–44]. A recent case series reported that iTBS is effective and safe as a treatment for depression during pregnancy [43]. The short duration of iTBS may appeal to patients with limited time or access to childcare. Another promising safe, effective, and non-invasive neuromodulation treatment is transcranial direct current stimulation (tDCS) [45]. This treatment device is portable and allows for at-home administration, further improving accessibility [46]. Future studies with a focus on the safety and efficacy of these devices in treating PPD are needed. Finally, our findings highlight the potential role of rTMS as an important treatment option for individuals who prefer to avoid antidepressant use during the peripartum period due to concerns regarding medication exposure during pregnancy and breastfeeding [14–20]. The non-systemic nature and limited side effect profile of rTMS may therefore address an important unmet need within this population [30, 47–52]. At the same time, rTMS does not necessarily need to replace pharmacotherapy and may also be used adjunctively alongside antidepressants when desired, as emerging literature suggests that combined treatment may enhance response in some patients [53]. The participant’s description of rTMS “intensifying” medication effects may reflect both a subjective perception of benefit and the possibility of additive therapeutic effects reported in prior research. More qualitative research with a focus on accessing treatment during the peripartum period is needed to better understand the generalizability of the reported findings and to uncover challenges that may be unique to certain communities not captured here. Conducting individual interviews is an important next step in achieving this. Limitations This study is limited by several factors. Firstly, participants with greater interest in alternative treatments may have been more likely to join the focus group, introducing potential selection bias. To minimize this, rTMS was not mentioned in the recruitment materials but was included in the information form provided upon sign-up. Secondly, our study had a small sample size of 9 participants, which limits generalizability, and percentages should be interpreted cautiously. This was in part due to a low attendance rate of 45%, with one participant going into labor, others withdrawing due to conflicting commitments, and some not providing a reason. Depressive symptoms and other responsibilities (i.e., childcare, appointments) may account for the low attendance rate. Thirdly, only participants living in Canada were recruited, again possibly limiting generalizability of the findings. However, since rTMS is available through both public health and private clinics, the results may still be applicable to other countries with similar healthcare models. Fourth, only participants living in urban communities participated in the focus groups. While the discussion included topics of location and accessibility, input from rural participants could have offered a different perspective. Additionally, 77.8% of participants identified as Caucasian, which may have resulted in an underrepresentation of barriers and perspectives more commonly experienced by marginalized racial and ethnic communities, such as cultural stigma surrounding mental illness, mistrust of medical technologies or healthcare systems, language barriers, and inequities in access to care. As such, caution should be exercised in generalizing these findings across diverse cultural and ethnic populations. Finally, the focus groups were designed to explore awareness, perceptions, and acceptability of rTMS rather than to comprehensively characterize participants’ mental health symptoms or current treatment regimens. As such, detailed information regarding symptom severity, diagnostic status, prior treatments for PPD, including whether participants met criteria for TRD, and ongoing management strategies was not systematically collected. Although some participants referenced previous treatment experiences during discussion, these were not directly prompted by the facilitator. The absence of systematically collected clinical and treatment history data limits interpretation of how illness severity, treatment resistance, or prior management may have influenced participants’ perspectives on rTMS. Additionally, because eligibility for publicly funded rTMS services was not systematically assessed, it remains unclear whether reported financial barriers reflected true ineligibility for public coverage or limited awareness of available publicly funded treatment pathways. Given that publicly funded rTMS services for TRD are not consistently available across Canadian provinces, interpretations of treatment cost and accessibility should therefore be made cautiously. Conclusion Limited awareness of rTMS among patients and health providers, financial challenges, and physical accessibility were discussed as significant barriers to accessing this treatment. All participants expressed interest in learning more about rTMS and were particularly attracted to its safety and non-invasive quality; however, some participants expressed reservations about receiving treatment during pregnancy due to uncertainty regarding its potential impact on their child’s well-being. Recommendations for addressing this knowledge gap included conferences/workshops and educational material for health providers, as well as case studies and testimonials shared through social media and traditional news for patients and the public. More research and awareness of rTMS for PPD are needed due to its safety, effectiveness, and potential for quicker access through direct referrals from general practitioners and nurse practitioners. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Abbreviations Canadian Network for Mood and Anxiety Treatments Food and Drug Administration Intermittent theta burst stimulation Obstetricians/gynecologists Peripartum depression Repetitive transcranial magnetic stimulation Sequenced Treatment Alternatives to Relieve Depression Transcranial direct current stimulation Treatment resistant depression Author contributions HFA: Conceptualization, design, data collection, analysis, writing- original draft, and writing- review and editing. RD: data collection, analysis, writing- original draft, and writing- review and editing. MJ: Conceptualization, design, analysis, and writing- review and editing. LB: Conceptualization, design, and writing- review and editing. GW: Design, and writing- review and editing. BC: Conceptualization, design, and writing- review and editing. X-ML: Conceptualization, design, and writing- review and editing. AJG: Conceptualization, design, and writing- review and editing. YZ: Conceptualization, design, and writing- review and editing. Funding This study was supported by the Start-up Fund (RES0052505) from the University of Alberta to YZ. Data availability The data collected in this research can be accessed by contacting the corresponding author. Declarations Ethics approval and consent to participate Ethical approval was obtained from the University of Alberta Research Ethics Office (Pro00114151). Informed verbal consent was obtained from all participants. This study was conducted in accordance with the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data collected in this research can be accessed by contacting the corresponding author.